Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DX25F6XRY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $113,750
Award facts
- Contract value 100% obligated
- $113,749.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $113,749.65 for STELARA 90 mg/mL syringes. The contract, awarded on September 3, 2025, with an ultimate completion date of September 24, 2025, is funded by the Defense Logistics Agency's Medical Supply Chain division. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on the basis of its established capabilities as a federal pharmaceutical supplier. STELARA is a biologic immunosuppressant medication commonly used to treat autoimmune conditions, and this award represents a continuation of the company's role in supplying specialized pharmaceutical products to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499,999,999 single-award vehicle valid through November 2026. The IDC enables the Defense Logistics Agency to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military health facilities worldwide. As a consistent performer in federal pharmaceutical procurement, DMS Pharmaceutical Group has demonstrated the capability to reliably deliver specialized medical products to support the Department of Defense's healthcare operations and supply chain requirements.
Quick answers
Who was awarded contract SPE2DX25F6XRY?
SPE2DX25F6XRY was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on September 3, 2025.
How much is contract SPE2DX25F6XRY worth?
The government has obligated $113,750 on SPE2DX25F6XRY.
Is contract SPE2DX25F6XRY an order under another contract?
Yes. SPE2DX25F6XRY is a delivery order under SPE2DX15D9168, an indefinite delivery contract.
Was contract SPE2DX25F6XRY competed?
The extent of competition for SPE2DX25F6XRY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award